Journal of Clinical Oncology 31:193, 2013 58 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 32. Boussiotis VA, Freeman GJ, Gri bben JG, et al: The critical role of CD28 signalling in the prevention of human T-cell anergy. Res Immunol 146:140-9, 1995 33. Hodge JW, Greiner JW, Tsang KY, et al: Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 11:788-803, 2006 34. Sharpe AH, Freeman GJ: The B7 -CD28 superfamily. Nat Rev Immunol 2:116-26, 2002 35. Riley JL, June CH: The CD28 family: a T- cell rheostat for therapeutic control of T-cell activation. Blood 105:13-21, 2005 36. Wingren AG, Parra E, Varga M, et al: T cell activation pathways: B7, LFA-3, and ICAM -1 shape unique T cell profiles. Crit Rev Immunol 15:235-53, 1995 37. Lebedeva T, Dustin ML, Sykulev Y: ICAM- 1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 17:251-8, 2005 38. Wang Y, Shibuya K, Yamashita Y, et al: LFA-1 decreases the antigen dose for T cell activation in vivo. Int Immunol 20:1119-27, 2008 39. Hodge JW, Sabzevari H, Yafal AG, et al: A triad of costimulatory molecules synergize to amplify T -cell activation. Cancer Res 59:5800-7, 1999 40. Litzinger MT, Foon KA, Tsang KY, et al: Comparative analysis of MVA- CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. Leuk Res 34:1351-7, 2010 41. Blanchard TJ, Alcami A, Andrea P, et al: Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 ( Pt 5):1159-67, 1998 42. Alcami A, Smith GL: A soluble receptor for interleukin- 1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-67, 1992 43. Antoine G, Scheiflinger F, Dorner F, et al: The complete genomic sequence of the modified vaccinia Ankar a strain: comparison with other orthopoxviruses. Virology 244:365-96, 1998 44.